270 studies found for:    "Expanded Access" [STUDY-TYPES]
Show Display Options
Download search resultsDownload the search results for:
"Expanded Access" [STUDY-TYPES] (270 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Approved for marketing Korean Early Access Program
Condition: Leukemia
Intervention: Drug: Dasatinib
2 Available Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
3 No longer available An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada
Condition: HIV Infection
Intervention: Drug: Efavirenz
4 Available Humanitarian Use of AVANTA Orthopaedics Proximal Interphalangeal Joint
Condition: Arthroplasty of the PIP Joint
Intervention: Device: SR™ PIP
5 Temporarily not available Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar)
Condition: Pulmonary Embolism
Intervention: Drug: Gadofosveset Triodium
6 Unknown  Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy
Condition: Multiple Myeloma
Intervention: Drug: Bortezomib/Dexamethasone/Melphalan
7 No longer available Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions: Major Depressive Disorder;   Fibromyalgia;   Diabetic Peripheral Neuropathic Pain;   Generalized Anxiety Disorder
Intervention: Drug: Duloxetine Hydrochloride
8 Approved for marketing A Treatment-Option Study of Brentuximab Vedotin in Patients With Progression of Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma
Conditions: Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention: Drug: brentuximab vedotin
9 Available Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
Condition: Non-small Cell Lung Cancer (NSCLC)
Intervention: Drug: LDK378
10 Approved for marketing Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib
11 Temporarily not available Early Access of TMC207 in Patients With Extensively Drug Resistant or Pre-XDR Pulmonary Tuberculosis
Condition: Tuberculosis
Intervention: Drug: TMC207
12 No longer available Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases
Condition: Prostatic Neoplasms
Intervention: Drug: Radium-223 dichloride (BAY88-8223)
13 Available Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Condition: Hypertension, Pulmonary
Intervention: Drug: Adempas (Riociguat, BAY63-2521)
14 Available Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome
Condition: Lambert Eaton Myasthenic Syndrome
Intervention: Drug: 3, 4-Diaminopyridine
15 Available Accuracy and Reliability of GSA for Remnant Liver Function
Condition: Both Benign and Malignant Liver Mass
Intervention: Device: 99mTc-GSA
16 No longer available Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)
Condition: Metachromatic Leukodystrophy
Intervention: Biological: Enriched Hematopoetic Stem Cell Transplant
17 Available An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Condition: Metastatic Breast Cancer
Intervention: Drug: Eribulin Mesylate
18 No longer available Compassionate Use of the Becker Expander/Breast Implant
Condition: Breast Reconstruction
Interventions: Device: Becker 50 Expander/Breast implant;   Device: Becker 25 Expander/Breast implant
19 Available Compassionate Use of Triheptanoin (C7) for Fatty Acid Oxidation Disorders and Glycogen Storage Disease
Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency;   Carnitine Palmitoyltransferase Deficiencies (CPT1, CPT2);   Mitochondrial Trifunctional Protein Deficiency;   Long-chain Hydroxyacyl-CoA Dehydrogenase Deficiency;   Glycogen Storage Disorders;   Pyruvate Carboxylase Deficiency, Type B;   Acyl-coA Dehydrogenase, Type 9
Intervention: Drug: triheptanoin
20 No longer available Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
Condition: West Nile Virus Infection
Intervention: Biological: MGAWN1

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years